Monday's Health Winners & Losers - TheStreet

AtheroGenics

( AGIX) dropped nearly 60% after the company's heart-disease drug failed to reach its primary goal in a Phase III trial. The stock was tumbling $4.63 at $3.20.

Sepracor

( SEPR) was also trading lower after Friedman Billings downgraded the stock to underperform from market perform. The firm also cut its stock price target for Sepracor to $43 from $58, citing weaker-than-expected sales of the company's sleep drug Lunesta. Sepracor was off $1.24, or 2.6%, to $46.62.

Elsewhere,

MedcoHealth

(MHS)

was rising 2.8% to $69.97.

UnitedHealth

(UNH) - Get Report

tacked on 2.4% to $54.39.

Wyeth

( WYE) was higher by 2.1% at $49.27.

Among decliners,

Hollis-Eden Pharmaceuticals

( HEPH) was down 6.2% to $3.05.

Avanir Pharmaceutical

(AVNR)

was falling 3.7% to $1.32.

CV Therapeutics

( CVTX) was lower by 1.8% at $9.13.